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ABSTRACT. Copper-based oxide glass-ceramic was successfully synthesized through the single-step melt 
annealing technique. Synthesized glass-ceramics was characterized using X-ray diffraction (XRD) and scanning 
electron microscopy (SEM) supported with energy dispersive X-ray (EDX) and mapping. Pyrazolo[1,5-
a]pyrimidines 5a-f were synthesized via the reaction of 5-amino-1H-pyrazole-4-carboxamide (1) with enaminones 
2a-f in the presence of synthesized oxide glass-ceramic catalyst powder under solvent-free condition. The 
molecular docking study demonstrated that the COVID-19 main protease (MPro) inhibitor. 
  




During the last decades, several authors devoted their efforts to increasing the yield of specific 
known reactions or to reduce the time of reactions through the usage of a new catalyst [1] or to 
modify already used catalyst and/or converting already used one to their nanoscale [2]. 
Copper-based catalysts proved to have good activity for the water-gas shift reactions with no 
methanation activity so they are well suited for use in water-gas shift duties. However, because 
copper catalysts are particularly pruned to easy sintering, they can only be used with low 
temperatures operations [3]. 
Catalysts prepared from mixed oxides of copper and zinc were being demonstrated, but the 
problem of producing catalyst with sufficiently long life to become a commercial proposition 
was not resolved [4], therefore additives of aluminum oxide and silicon dioxide were added to 
act as a glass network matrix that holds constituents via covalent bonding between constituents 
[5]. 
 Pyrazolo[1,5-a]pyrimidines have diverse biological activities [6-12] such as compound A, 
pyrazolo[1,5-a]pyrimidine benzoic acid derivative, act as an antimicrobial agent [13]. 
Compound B, N1-(2,5-dimethyl-3-p-tolylpyrazolo[1,5-a]pyrimidin-7-yl)-1,3-diamine derivative, 
act as a potent hepatitis C virus inhibitor [14]. Compound C, 4-(6-(4-(1-(pyrrolidin-1-
yl)ethyl)phenyl)pyrazolo[1,5-a]pyrimidin-3-yl)naphthalene-1-sulfonamide, act as a potent and 
selective ALK2 inhibitor [15]. Recently, Attia et al. have synthesized the two derivatives, 7-(4-
methoxyphenyl)-pyrazolo[1,5-a]pyrimidine-3,6-dicarbonitrile (D) and 7-(naphthalen-2-yl)-
pyrazolo[1,5-a]pyrimidine-3-carbonitrile (E), which have a potent anti-proliferative activity 
[16]. Also, Singleton et al. have synthesized 3-(1H-benzo[d]imidazol-2-yl)pyrazolo[1,5-
a]pyrimidine (F) which act as a selective inhibitor of JAK1 JH2 pseudokinase [17]. 
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Furthermore, some structures of drugs of pyrazolo[1,5-a]pyrimidine such as Zaleplon is a drug 
used to treat insomnia; Dinaciclib (SCH-727965) is a cyclin-dependent kinases inhibitor drug. 




Figure 1. Some importantpyrazolo[1,5-a]pyrimidines (A-F). 
 
From the above facts and in continuation of our targets [18-33], the presented work aims to 
introduce a new efficient copper-based oxide glass-ceramic as a catalyst in the synthesis of 
pyrazolo[1,5-a]pyrimidines 5a-f under solvent-free condition. The work extended to study with 




Catalyst preparation and characterization 
 
Copper-based oxide glass-ceramic catalyst was prepared via a simple melt annealing technique. 
Pre-calculated amounts of analytical grade chemical of copper oxide, aluminum oxide, zinc 
oxide, and silicon dioxide were used for the synthesis of the glass-ceramic catalyst of nominal 
composition 30SiO2-35ZnO-25CuO-10Al2O3 mol%. Mixed powder melted in a muffle furnace 
in a platinum crucible at a temperature 135020 °C. The melt was swirled at a constant time 
interval to ensure homogeneity and bubble-free samples. The obtained melt was poured over a 
preheated stainless steel mold and transferred immediately to the annealing oven. The oven was 
then turned off and allowed to cool to room temperature with a cooling rate of 20 °C/h. 
Synthesized glass-ceramic was analyzed via XRD to identify possible present crystalline 
phases that precipitated within the sample during annealing process. Obtained sample was 
ground and the fine powder was examined using a Philips PW 1390 X-ray diffractometer 
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adopting Ni-filter and Cu-target operating at 30 kV. Obtained pattern recognized with an 
iterative comparison with standard JCPDS, ASTM cards, and published data. 
Scanning electron microscopic (SEM) study carried out on powdered sample coated with a 
thin layer of gold using JSM-7500F field emission microscope supported with EDAX unit using 
accelerating voltage 30 kV, magnification up to 400,000.  
 
Preparation of pyrazolo[1,5-a]pyrimidines 5a-f 
 
One mole of 5-amino-3-(4-methoxyphenylamino)-N-phenyl-1H-pyrazole-4-carboxamide (1) 
was added to one mole of enaminones 2a-f in the presence of catalytic amount (10 wt%) of the 
prepared oxide glass-ceramic powder under solvent-free condition at 60-70 oC, after the 
appropriate time the reaction was worked up using water and the organic compounds were 
extracted using ethyl acetate. After the separation and drying process the product was 
characterized as 7-aryl-2-(arylamino)pyrazolo[1,5-a]pyrimidine-3-carboxamides 5a-f [34]. 
 
2-(4-Methoxyphenylamino)-N,7-diphenylpyrazolo[1,5-a]pyrimidine-3-carboxamide(5a). Yellow 
crystals, m.p. 218–220 °C, yield (72%). IR (KBr) νmax/cm
−1 3346 (NH), 1658 (C=O). 1H-NMR 
(CDCl3, 400 MHz, δ ppm): 3.80 (s, 3H, OCH3), 6.88 (d, 2H, J = 9.0 Hz, ArH), 6.96 (d, 1H, J = 
4.8 Hz, pyrimidine), 7.12 (t, 1H, ArH), 7.36-7.42 (m, 5H, ArH), 7.62 (d, 2H, J = 9.0 Hz, ArH), 
7.74 (d, 2H, J = 8.4 Hz, ArH), 8.11 (d, 2H, J = 8.3 Hz, ArH), 8.49 (d, 1H, J = 4.8 Hz, 
pyrimidine), 9.40 (s, 1H, NH), 10.05 (s, 1H, NH). 13C-NMR (CDCl3, 100 MHz, δ ppm): 55.7 (C, 
OCH3), 87.8 (C, C3-pyrazolopyrimidine), 107.0 (C, C6-pyrazolopyrimidine), 114.4, 119.2, 
120.2, 123.7, 127.7, 129.1, 129.5, 129.6 (14C, Ar), 134.1 (C, C3a-pyrazolopyrimidine), 138.8, 
142.4, 146.7 (3C, Ar), 147.9 (C, C7-pyrazolopyrimidine), 149.6 (C, Ar), 154.5 (C, C2-
pyrazolopyrimidine), 157.8 (C, C5-pyrazolopyrimidine), 163.3 (C=O). MS (m/z, %): 435 (M
+, 
73.86). Anal. calcd. (%) for C26H21N5O2 (435.48): C, 71.71; H, 4.86; N, 16.08. Found: C, 71.80; 
H, 4.81; N, 16.00%. 
 
2-(4-Methoxyphenylamino)-N-phenyl-7-(4-methylphenyl)-pyrazolo[1,5-a]pyrimidine-3-
carboxamide (5b). Yellow crystals, m.p. 219–221 °C, yield (77%). IR (KBr) νmax/cm
−1 3337 
(NH), 1658 (C=O). 1H-NMR (CDCl3, 400 MHz, δ ppm): 2.49 (s, 3H, CH3), 3.80 (s, 3H, 
OCH3), 6.87 (d, 2H, J = 8.9 Hz, ArH), 6.91 (d, 1H, J = 4.7 Hz, pyrimidine), 7.12 (t, 1H, ArH), 
7.36 (d, 2H, J = 8.3 Hz, ArH), 7.38 (t, 2H, ArH), 7.60 (d, 2H, J = 8.9 Hz, ArH), 7.73 (d, 2H, J = 
7.6 Hz, ArH), 8.08 (d, 2H, J = 8.1 Hz, ArH), 8.43 (d, 1H, J = 4.7 Hz, pyrimidine), 9.38 (s, 1H, 
NH), 10.01 (s, 1H, NH). 13C-NMR (CDCl3, 100 MHz, δ ppm): 21.8 (C, CH3), 55.7 (C, OCH3), 
87.7 (C, C3-pyrazolopyrimidine), 107.0 (C, C6-pyrazolopyrimidine), 114.4, 119.1, 120.1, 123.7, 
127.6, 129.1, 129.4, 129.6 (14C, Ar), 134.1 (C, C3a-pyrazolopyrimidine), 138.8, 142.3, 146.6 
(3C, Ar), 147.8 (C, C7-pyrazolopyrimidine), 149.6 (C, Ar), 154.4 (C, C2-pyrazolopyrimidine), 
157.7 (C, C5-pyrazolopyrimidine), 163.3 (C=O). MS (m/z, %): 449 (M
+, 67.43). Anal. calcd. 
(%) for C27H23N5O2 (449.50): C, 72.14; H, 5.16; N, 15.58. Found: C, 72.10; H, 5.20; N, 15.60%. 
 
7-(4-Methoxyphenyl)-2-(4-methoxyphenylamino)-N-phenylpyrazolo[1,5-a]pyrimidine-3-
carboxamide (5c). Yellow crystals, m.p. 206–208 °C, yield (76%). IR (KBr) νmax/cm
−1 3340 
(NH), 1646 (C=O). 1H-NMR (CDCl3, 400 MHz, δ ppm): 3.80 (s, 3H, OCH3), 3.91 (s, 3H, 
OCH3), 6.87 (d, 2H, J = 8.9 Hz, ArH), 6.89 (d, 1H, J = 4.8 Hz, pyrimidine), 7.05 (d, 2H, J = 8.8 
Hz, ArH), 7.11 (t, 1H, ArH), 7.37 (t, 2H, ArH), 7.60 (d, 2H, J = 8.9 Hz, ArH), 7.72 (d, 2H, J = 
7.6 Hz, ArH), 8.18 (d, 2H, J = 8.8 Hz, ArH), 8.40 (d, 1H, J = 4.8 Hz, pyrimidine), 9.36 (s, 1H, 
NH), 10.02 (s, 1H, NH). 13C-NMR (CDCl3, 100 MHz, δ ppm): 55.5 (C, OCH3), 55.6 (C, OCH3), 
87.4 (C, C3-pyrazolopyrimidine), 106.4 (C, C6-pyrazolopyrimidine), 113.9, 114.2, 119.0, 120.0, 
122.4, 123.5, 128.9, 131.3 (14C, Ar), 134.0 (C, C3a-pyrazolopyrimidine), 138.6, 146.0 (2C, Ar), 
147.7 (C, C7-pyrazolopyrimidine), 149.3 (C, Ar), 154.3 (C, C2-pyrazolopyrimidine), 157.5 (C, 
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C5-pyrazolopyrimidine), 162.2 (C, Ar), 163.2 (C=O). MS (m/z, %): 465 (M
+, 69.48). Anal. 




carboxamide (5d). Yellow crystals, m.p. 252–253 °C, yield (72%). IR (KBr) νmax/cm
−1 3343 
(NH), 1648 (C=O). 1H-NMR (CDCl3, 400 MHz, δ ppm): 3.81 (s, 3H, OCH3), 6.88 (d, 2H, J = 
9.0 Hz, ArH), 6.94 (d, 1H, J = 4.7 Hz, pyrimidine), 7.13 (t, 1H, ArH), 7.39 (t, 2H, ArH), 7.58 (d, 
4H, J = 8.8 Hz, ArH), 7.74 (d, 2H, J = 8.6 Hz, ArH), 8.15 (d, 2H, J = 8.7 Hz, ArH), 8.52 (d, 1H, 
J = 4.7 Hz, pyrimidine), 9.42 (s, 1H, NH), 9.99 (s, 1H, NH). 13C-NMR (CDCl3, 100 MHz, δ 
ppm): 55.7 (C, OCH3), 88.0 (C, C3-pyrazolopyrimidine), 107.0 (C, C6-pyrazolopyrimidine), 
114.4, 119.2, 120.2, 123.8, 129.1, 129.1, 130.9, 131.8 (14C, Ar), 133.9 (C, C3a-
pyrazolopyrimidine), 134.6, 138.0, 138.7 (3C, Ar), 145.3 (C, C7-pyrazolopyrimidine), 149.7 (C, 
Ar), 154.6 (C, C2-pyrazolopyrimidine), 157.9 (C, C5-pyrazolopyrimidine), 163.2 (C=O). MS 
(m/z, %): 469 (M+, 78.23). Anal. calcd. (%) for C26H20ClN5O2 (469.92): C, 66.45; H, 4.29; N, 
14.90. Found: C, 66.40; H, 4.30; N, 14.95%. 
 
7-(4-Bromophenyl)-2-(4-methoxyphenylamino)-N-phenylpyrazolo[1,5-a]pyrimidine-3-
carboxamide (5e). Yellow crystals, m.p. 278-280 °C, yield (69%). IR (KBr) νmax/cm
−1 3365 
(NH), 1650 (C=O). 1H-NMR (DMSO-d6, 400 MHz, δ ppm): 3.73 (s, 3H, OCH3), 6.93 (d, 2H, J 
= 9.0 Hz, ArH), 7.12 (t, 1H, ArH), 7.39 (t, 2H, ArH), 7.41 (d, 1H, J = 4.8 Hz, pyrimidine), 7.59 
(d, 2H, J = 9.0 Hz, ArH), 7.73 (d, 2H, J = 7.6 Hz, ArH), 7.90 (d, 2H, J = 8.7 Hz, ArH), 8.20 (d, 
2H, J = 8.7 Hz, ArH), 8.74 (d, 1H, J = 4.8 Hz, pyrimidine), 9.26 (s, 1H, NH), 10.03 (s, 1H, NH). 
13C-NMR (DMSO-d6, 100 MHz, δ ppm): 55.7 (C, OCH3), 87.6 (C, C3-pyrazolopyrimidine), 
106.9 (C, C6-pyrazolopyrimidine), 114.4, 119.1, 120.5, 123.3, 129.4, 129.8, 131.0, 131.6 (14C, 
Ar), 133.7 (C, C3a-pyrazolopyrimidine), 133.4, 136.1, 138.7 (3C, Ar), 145.2 (C, C7-
pyrazolopyrimidine), 149.5 (C, Ar), 154.8 (C, C2-pyrazolopyrimidine), 157.1 (C, C5-
pyrazolopyrimidine), 163.7 (C=O). MS (m/z, %): 514 (M+, 81.26). Anal. calcd. (%) for 
C26H20BrN5O2 (514.37): C, 60.71; H, 3.92; N, 13.62. Found: C, 60.65; H, 3.97; N, 13.65%. 
 
7-(4-Fluorophenyl)-2-(4-methoxyphenylamino)-N-phenylpyrazolo[1,5-a]pyrimidine-3-
carboxamide (5f). Yellow crystals, m.p. 237-239 °C, yield (70%). IR (KBr) νmax/cm
−1 3343 
(NH), 1647 (C=O). 1H-NMR (DMSO-d6, 400 MHz, δ ppm): 3.73 (s, 3H, OCH3), 6.91 (d, 2H, J 
= 9.0 Hz, ArH), 7.11 (t, 1H, ArH), 7.37 (d, 1H, J = 4.9 Hz, pyrimidine), 7.39 (d, 2H, J = 7.6 Hz, 
ArH), 7.52 (t, 2H, ArH), 7.58 (d, 2H, J = 9.0 Hz, ArH), 7.71 (d, 2H, J = 8.6 Hz, ArH), 8.31 (d, 
2H, J = 8.9 Hz, ArH), 8.71 (d, 1H, J = 4.8 Hz, pyrimidine), 9.23 (s, 1H, NH), 10.01 (s, 1H, NH). 
13C-NMR (DMSO-d6, 100 MHz, δ ppm): 55.2 (C, OCH3), 86.7 (C, C3-pyrazolopyrimidine), 
108.3 (C, C6-pyrazolopyrimidine), 114.3, 115.7, 115.9, 118.8, 119.4, 123.5, 126.4, 129.1 (14C, 
Ar), 132.4 (C, C3a-pyrazolopyrimidine), 133.3, 138.4 (2C, Ar), 145.0 (C, C7-
pyrazolopyrimidine), 147.1 (C, Ar), 151.1 (C, C2-pyrazolopyrimidine), 154.1 (C, C5-
pyrazolopyrimidine), 156.6 (C, Ar), 162.2 (C=O). MS (m/z, %): 453 (M+, 87.33). Anal. calcd. 
(%) for C26H20FN5O2 (453.47): C, 68.86; H, 4.45; N, 15.44. Found: C, 68.95; H, 4.40; N, 
15.50%. 
 
RESULTS AND DISCUSSION 
 
Characterization of the synthesized catalyst  
 
Figure 1 reveals the X-ray diffraction pattern of the synthesized copper-based glass-ceramic 
catalyst. The obtained pattern shows multiple sharp bands superimposed on a broad background 
spectrum. The background spectrum with attributed to the amorphous silicate network while the 
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sharp bands were attributed to the precipitated crystalline phases during the annealing process. It 
was observed that the spectrum refers to a crystalline multiphase structure consists of at least 




Figure 1. XRD pattern of the prepared catalyst. 
 
Scanning electron microscopy images supported with EDAX (SEM/EDAX) shown in 
Figure 2 reveals the same result retained from the XRD pattern in addition to more information 
about the surface morphology and composition. A homogenous sample with normal elemental 
distribution without voids or clusters was shown in Figure 2a. Mapping image Figure 2b 
supports the homogeneity of distribution while Figure 2c introduces the analysis of a presented 
component with an agreement with that used in the synthesis process. 
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The most common traditional method for the synthesis of 7-aryl-2-(phenylamino)pyrazolo[1,5-
a]pyrimidine-3-carboxamide 5a-f via the reaction of 5-amino-3-(4-methoxyphenylamino)-N-
phenyl-1H-pyrazole-4-carboxamide (1) with enaminones 2a-f in refluxed CH3COOH [34]. And 
towards, the aim of our research group for discovering new green methods for the synthesis of 
organic compounds [35-39]. The pyrazolo[1,5-a]pyrimidines 5a-f were prepared under solvent-
free conditions in the presence of green, cheap, and recyclable catalyst composed of glass-
ceramic oxides powder. The obtained results explained that the suggested catalytic method gives 




Scheme 1. Synthesis of compound 5a-f. 
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The suggested mechanism was explained as one can see in Scheme 1. The enamine was 
activated by the catalyst through the coordinate bond with an amino group in enamine and 
converted it to quaternary amine form which considered as a good leaving group than tertiary 
amine and in the second step, catalyst plays an important role in the activation of enone group 
by increase the polarization of carbonyl group. In the final step the intermediate loss of water 
molecules and give the stable form pyrazolo[1,5-a]pyrimidines 5a-f. 
 
Table 1. Synthesis of pyrazolopyrimidines 5a-f from 5-aminopyrazole and enaminones. 
 
Entry Ar Yield (%) Time (h) 
1 5a C6H5 88 9 
2 5b 4-CH3-C6H4- 86 10 
3 5c 4-CH3O-C6H4- 90 5 
4 5d 4-Cl-C6H4- 93 6 
5 5e 4-Br-C6H4- 91 8 
6 5f 4-F-C6H4- 92 5 
 
From the data showed in Table 1, we noticed that when (Ar) substituted by the electron-
withdrawing groups like the presence of halogens in para position reaction gives more yield and 
less reaction time. Besides, the presence of an electron releasing group in the aromatic ring at 
(Ar) gives lower yields and less reaction time. 
 
Molecular docking study  
 
The affinity and efficacy of the drug can be expected using molecular docking software. The 
binding between active sites in the COVID-19 main protease (Mpro) as a targeting enzyme was 
docked by pyrazolopyrimidines. The result was obtained by comparison with 
hydroxychloroquine as a reference molecule. Hydroxychloroquine during the last few months 
considered a promised candidate drug for Covid-19. In this special corona virus pandemic, Mpro 
is considered as a valuable target and unique challenge. The active binding site is presented by 
Liu et al. [40] and in the extension of our research group [41-44] to discover new efficient 
ligand-receptor interaction. 
The E-score (energy score in kcal/mol) is considered as one of the significant factors that 
explained the binding process between the ligand and enzyme. The molecular docking 
validation clarifies the interaction (E-score) between pyrazolopyrimidines 5a-f with a Mpro 
enzyme as -6.93, -8.24, -6.93, -6.88, -7.63, and -6.88, respectively. The calculated data 
explained that the protease active site protein residues are Asn 142, Thr 45, Thr 26, Glu 166, His 
41, Thr 25, Gln 192, Thr 190, Arg 188, Ala 191, Met 165, Leu 167, Leu 141, Asp 187, Thr 42, 
Pro 168, His 164, Gly 143, Ser 144, Cys 145, Gln 189, Met 49, Leu 27, Ser 46, Cys 44. Figures 
3a and 3b showed the 2D and 3D interaction diagrams with Mpro. 
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Figure 3a. 2D of the drug ligand interaction between 5e and Mpro enzyme active side. 
 
The drug-ligand electrostatic force-distance measurements 
 
The measured distance also reflects good drug ligand interaction. For example, we presented the 
drug-ligand electrostatic force-distance measurements for compound 5e the hydrogen bond 
distance between Thr 26 and the bromo group equal 3.31; the π-π stacking also presented 
between Gln 189 and Met 49 with the two aromatic rings. This compound presented 7 
intramolecular forces that presented the high drug ligand interaction.   
 
 
Figure 3b. The distance measurements in 3D interaction diagrams of 5e with Mpro enzyme 
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In conclusion, the oxide glass-ceramic catalyst powder was prepared and characterized. The 
prepared catalyst was applied successfully in the synthesis of pyrazolo[1,5-a]pyrimidines 5a-f 
via the reaction of 5-amino-1H-pyrazole-4-carboxamide 1 with enaminones 2a-f under solvent-
free condition. The molecular docking study proved that the prepared compounds presented 
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